One-of-a-Kind Clinic Offers Hope!

We're living in an unprecedented time of mood disorders that are literally crippling millions of people around the world. In fact, the World Health Organization reported this year that over 264 million people from all walks of life suffer from depression.

It's sad to say, but even in this day and age, 76% of people in low-income nations and 85% of people in middle-income countries receive no treatment for their mental disorders. Plus, around 800,000 people die from suicide every year. Today's traditional approaches to these problems clearly aren't working as they should.

Dr. Roger McIntyre, President of the Canadian Rapid Treatment Centre of Excellence (CRTCE), fully recognizes the scope of the problem. He's a world-renowned expert and researcher in the field of depressive disorders, and he's 100% correct when he observes that 'We have a large sub population in our country with depression who can't work… they just can't break this vicious cycle.'

There's hope on the horizon for people who suffer from depression, anxiety, and other mood disorders even if old, established medications can't help them. That hope comes in the form of ketamine, which was once thought of as a recreational drug but is now better understood as a potential treatment for those who struggle with depression.

Ketamine's potential in this area hasn't gone unnoticed by the scientific community. Dr. McIntyre observes a vast differential between the old and new approaches to treating depression: 'Most antidepressants take approximately four, six or even eight weeks to work. That's a long time… If you're suffering, ketamine can work within one day.'

Dr. David Gratzer, a psychiatrist at the Centre for Addiction and Mental Health (CAMH), strikes a similarly optimistic tone to Dr. McIntyre. Regarding ketamine, Gratzer says 'We are looking for a way of providing more rapid relief of depression than one might ordinarily see with Prozac and [similar] drugs.'

Dr. Gratzer also found 'evidence that it helps people very quickly, particularly people who have many thoughts of suicide.' There's no question that ketamine is now viewed as a cutting-edge treatment option that warrants more research and development.

Dr. Roger McIntyre. Courtesy:

The need for ambitious ketamine clinics is severe, and Dr. McIntyre and the CRTCE are answering the call for next-generation research and development in this area. In fact, the CRTCE was the first and only clinic of its kind in Canada to administer rapid-onset treatments for depression in the form of ketamine injections.

Moreover, the CRTCE is currently licensed by the College of Physicians and Surgeons
Ontario (CPSO) to perform ketamine treatments for indications including but not limited
to depression, bipolar disorder, PTSD, and OCD.

Ketamine has already been fast-tracked by Health Canada and the U.S. Food and Drug Administration for research and development with respect to depressive disorders. There's a huge market in the making here, and the prime beneficiary will be Champignon Brands (CAD: SHRM, US: SHRMF), which owns AltMed Capital Corp., which controls the CRTCE – the leading Canadian ketamine clinic operator.

The profit potential is staggering because ketamine clinics represent the future of depressive disorder treatment. And with over 1,500 ketamine treatments administered and over 300 patients serviced to date, the CRTCE is already proving itself as the epicenter of ketamine-focused R&D.

Champignon Brands and the CRTCE are true pioneers in ketamine research, and Champignon's bottom line will continue to expand as this promising therapeutic solution emerges step-by-step in the mainstream.


Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF)!

For further updates on Champignon Brands​, subscribe now!

    We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that we have been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

    Please read our full disclaimer at